Silence Therapeutics (NASDAQ:SLN) Earns Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of Silence Therapeutics (NASDAQ:SLN - Free Report) in a research note published on Friday,Benzinga reports. Chardan Capital currently has a $35.00 price objective on the stock.

Other equities analysts have also issued research reports about the stock. HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Friday. BMO Capital Markets dropped their price objective on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. The Goldman Sachs Group decreased their target price on Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a research note on Friday, May 9th. Finally, Morgan Stanley dropped their price target on Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $33.83.

Silence Therapeutics Stock Down 5.1%

Shares of NASDAQ SLN traded down $0.27 during trading on Friday, reaching $5.06. The company had a trading volume of 36,804 shares, compared to its average volume of 251,068. The stock has a market cap of $151.45 million, a P/E ratio of -3.22 and a beta of 1.41. The company's fifty day moving average price is $4.13 and its 200-day moving average price is $4.92. Silence Therapeutics has a 12 month low of $1.97 and a 12 month high of $22.47.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The firm had revenue of $0.14 million for the quarter, compared to the consensus estimate of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. As a group, equities analysts predict that Silence Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new position in Silence Therapeutics during the 4th quarter valued at $26,000. Barclays PLC increased its position in shares of Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after acquiring an additional 2,793 shares during the last quarter. Virtus ETF Advisers LLC lifted its holdings in Silence Therapeutics by 130.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock worth $74,000 after acquiring an additional 6,098 shares during the period. Ameriprise Financial Inc. bought a new stake in Silence Therapeutics during the fourth quarter worth $113,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Silence Therapeutics in the fourth quarter worth $134,000. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.